Finance

Lists
Why is SABS up ၃.၃၉%?
Dive Deeper
SABS:NASDAQ
SAB Biotherapeutics Inc
၃.၀၅ US$
+၃.၃၉%
(+၀.၁၀၀) 1D
နို ၁၈, GMT-၅ ၀၉:၄၀:၄၁  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
၃.၀၀ US$
High
၃.၀၅ US$
Low
၂.၉၅ US$
Mkt. cap
၂၇.၄၈ ကုဋေ
Avg. vol.
၆.၈၃ သိန်း
Volume
၁၈.၀၀
52-wk high
၅.၁၅ US$
52-wk low
၂.၄၄ US$
EPS
-၀.၉၃ US$
Beta
၀.၆၇
Shares outstanding
၉.၀၁ ကုဋေ
No. of employees
၈၆
Open
၃.၀၀ US$
High
၃.၀၅ US$
Low
၂.၉၅ US$
Mkt. cap
၂၇.၄၈ ကုဋေ
Avg. vol.
၆.၈၃ သိန်း
Volume
၁၈.၀၀
52-wk high
၅.၁၅ US$
52-wk low
၂.၄၄ US$
EPS
-၀.၉၃ US$
Beta
၀.၆၇
Shares outstanding
၉.၀၁ ကုဋေ
No. of employees
၈၆
News stories
From web sources and news partners
ChartMill
ChartMill
·
ပြီးခဲ့သည့် ၁ နာရီ
S&P 500 Premarket Movers on Nov. 18
TradingView
TradingView
·
ပြီးခဲ့သည့် ၅၀ မိနစ်
UBS predicts S&P 500 moving up 12% in 2027 but flags major risks around AI
Yahoo Finance
Yahoo Finance
·
ပြီးခဲ့သည့် ၂၅ မိနစ်
Investors Love the S&P 500 Index. Here’s Why I Don’t.
About SAB Biotherapeutics Inc
CEO-
Employees၈၆
Founded၂၀၁၄
HeadquartersMiami Beach, ဖလော်ရီဒါပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websitesab.bio
Analyst ratings
Based on 4 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current ၃.၀၅ US$
၁၅.၀၀ US$ (+၃၉၁.၈၀%)
Average
၁၃.၂၅ US$ (+၃၃၄.၄၃%)
Lowest
၁၁.၀၀ US$ (+၂၆၀.၆၆%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Oppenheimer
Buy
Reiterated
၁၄.၀၀ US$
+၃၅၉%
11/06/2026
Samantha Semenkow
Citi
Buy
Maintained
၁၁.၀၀ US$
+၂၆၀.၇%
11/05/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
၁၅.၀၀ US$
+၃၉၁.၈%
11/05/2026
Eliana Merle
Barclays
Buy
Maintained
၁၃.၀၀ US$
+၃၂၆.၂%
11/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
၁၀.၀၀ US$
+၂၂၇.၉%
08/06/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
၁၆.၀၀ US$
+၄၂၄.၆%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
၆.၀၀ US$
+၉၆.၇%
06/16/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
၁၄.၀၀ US$
+၃၅၉%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
၁၁.၀၀ US$
+၂၆၀.၇%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
၁၅.၀၀ US$
+၃၉၁.၈%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
၁၃.၀၀ US$
+၃၂၆.၂%
04/02/2026
Michael Yee
UBS
Buy
Maintained
၇.၀၀ US$
+၁၂၉.၅%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
-
-
-
-
Cost of goods sold
၉.၇၃ သန်း
၁.၃၄ ကုဋေ
၁.၆၂ ကုဋေ
၁.၈၁ ကုဋေ
Cost of revenue
၉.၇၃ သန်း
၁.၃၄ ကုဋေ
၁.၆၂ ကုဋေ
၁.၈၁ ကုဋေ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၆.၀၄ သန်း
၆.၆၀ သန်း
၇.၂၀ သန်း
၇.၈၂ သန်း
Operating expense
၆.၀၄ သန်း
၆.၆၀ သန်း
၇.၂၀ သန်း
၇.၈၂ သန်း
Total operating expenses
၁.၅၈ ကုဋေ
၂.၀၀ ကုဋေ
၂.၃၄ ကုဋေ
၂.၅၉ ကုဋေ
Operating income
-၁.၅၈ ကုဋေ
-၂.၀၀ ကုဋေ
-၂.၃၄ ကုဋေ
-၂.၅၉ ကုဋေ
Other non operating income
-၁.၇၃ သန်း
၁.၄၄ သိန်း
-၇.၆၁ သိန်း
၁.၉၉ သန်း
EBT including unusual items
-၁.၆၉ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၂၅ ကုဋေ
-၂.၂၃ ကုဋေ
EBT excluding unusual items
-၁.၆၉ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၂၅ ကုဋေ
-၂.၂၃ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၁.၆၉ ကုဋေ
-၁.၈၉ ကုဋေ
-၂.၂၅ ကုဋေ
-၂.၂၃ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၄၁
-
-၀.၂၈
-၀.၂၆
Interest and investment income
၇.၀၁ သိန်း
၁.၀၅ သန်း
၁.၇၁ သန်း
၁.၆၁ သန်း
Interest expense
-၆.၃၅ သောင်း
-၆.၂၇ သောင်း
-၆.၂၀ သောင်း
-
Net interest expenses
၆.၃၇ သိန်း
၉.၈၄ သိန်း
၁.၆၅ သန်း
၁.၆၁ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၁.၅၀ ကုဋေ
-၁.၉၂ ကုဋေ
-၂.၂၅ ကုဋေ
-၂.၅၁ ကုဋေ
Gain or loss from assets sale
-
-
-
-၆.၆၀ သောင်း
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ